0001209191-19-007440.txt : 20190205
0001209191-19-007440.hdr.sgml : 20190205
20190205174233
ACCESSION NUMBER: 0001209191-19-007440
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190201
FILED AS OF DATE: 20190205
DATE AS OF CHANGE: 20190205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HELLUMS RHONDA LYNETTE
CENTRAL INDEX KEY: 0001766456
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35952
FILM NUMBER: 19569078
MAIL ADDRESS:
STREET 1: C/O ARATANA THERAPEUTICS, INC.
STREET 2: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
CITY: LEAWOOD
STATE: KS
ZIP: 66211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARATANA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001509190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383826477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
CITY: LEAWOOD
STATE: KS
ZIP: 66211
BUSINESS PHONE: 913.353.1000
MAIL ADDRESS:
STREET 1: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
CITY: LEAWOOD
STATE: KS
ZIP: 66211
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2019-02-01
0
0001509190
ARATANA THERAPEUTICS, INC.
PETX
0001766456
HELLUMS RHONDA LYNETTE
C/O ARATANA THERAPEUTICS, INC.
11400 TOMAHAWK CREEK PARKWAY, SUITE 340
LEAWOOD
KS
66211
0
1
0
0
CHIEF FINANCIAL OFFICER
Common Stock
26501
D
Stock Option (Right to Buy)
22.91
2024-03-02
Common Stock
25000
D
Stock Option (Right to Buy)
17.18
2025-01-28
Common Stock
2650
D
Stock Option (Right to Buy)
3.14
2026-01-21
Common Stock
6700
D
Stock Option (Right to Buy)
8.02
2027-01-12
Common Stock
4100
D
Stock Option (Right to Buy)
4.83
2028-01-24
Common Stock
14700
D
Stock Option (Right to Buy)
4.22
2029-01-23
Common Stock
15100
D
Fully vested as of March 3, 2018.
Fully vested as of January 29, 2019.
Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates.
Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates.
Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and vests as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates.
Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2020 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Exhibit List: Exhibit 24 - Power of Attorney.
/s/ John C. Ayres as Attorney-in-Fact for Rhonda Lynette Hellums
2019-02-05
EX-24.3_830412
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Rhonda Hellums
With respect to holdings of and transactions in securities issued by Aratana
Therapeutics, Inc. (the "Company"), the undersigned hereby constitutes and
appoints the individuals named on Schedule A attached hereto and as may be
amended from time to time, or any of them signing singly, with full power of
substitution and resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the United States Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, and any other documents necessary or
appropriate to obtain and/or regenerate codes and passwords enabling the
undersigned to make electronic filings with the SEC of reports required by
Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or
regulation of the SEC;
2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance
with Section 16 of the Securities Exchange Act of 1934, as amended, and the
rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is any
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 1st day of February, 2019.
/s/ Rhonda Hellums
Rhonda Hellums
Schedule A
Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and
Resubstitution
1. Craig Tooman, President and Chief Executive Officer
2. John C. Ayres, VP-Corporate Development and Administration, General Counsel
& Secretary